A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects
A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE DOSE STUDY TO EVALUATE THE EFFECT OF RENAL IMPAIRMENT ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF RIVIPANSEL (PF-06460031) IN SUBJECTS WITH RENAL IMPAIRMENT AND IN HEALTHY SUBJECTS
Sponsor: GlycoMimetics Incorporated
Listed as NCT02813798, this PHASE1 trial focuses on Healthy and Renal Impairment and remains completed. Sponsored by GlycoMimetics Incorporated, it has been updated 11 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jul 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2020 — Jul 2020 [monthly]
Completed PHASE1
▶ Show 6 earlier versions
-
Jul 2019 — Jun 2020 [monthly]
Completed PHASE1
-
Jun 2018 — Jul 2019 [monthly]
Completed PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jun 2017 — Mar 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlycoMimetics Incorporated
For direct contact, visit the study record on ClinicalTrials.gov .